Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
15 avr. 2024 09h36 HE
|
Immix Biopharma, Inc.
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix...
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
20 mars 2024 09h46 HE
|
Immix Biopharma, Inc.
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
05 mars 2024 09h35 HE
|
Immix Biopharma, Inc.
LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma 12 Month Review Progress Update
21 févr. 2024 09h31 HE
|
Immix Biopharma, Inc.
LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its...
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
08 févr. 2024 16h45 HE
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies...
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
07 févr. 2024 09h37 HE
|
Immix Biopharma, Inc.
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU...
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
05 févr. 2024 22h30 HE
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies...
Immix Biopharma Announces Proposed Public Offering of Common Stock
05 févr. 2024 15h20 HE
|
Immix Biopharma, Inc.
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease,...
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
24 janv. 2024 08h35 HE
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
04 janv. 2024 09h34 HE
|
Immix Biopharma, Inc.
LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined...